122 related articles for article (PubMed ID: 27130795)
1. Trends in Disclosures of Industry Sponsorship.
Ahmed AA; Holliday EB; Fakhreddine M; Yoo SK; Deville C; Jagsi R
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1093-101. PubMed ID: 27130795
[TBL] [Abstract][Full Text] [Related]
2. Does Cancer Literature Reflect Multidisciplinary Practice? A Systematic Review of Oncology Studies in the Medical Literature Over a 20-Year Period.
Holliday EB; Ahmed AA; Yoo SK; Jagsi R; Hoffman KE
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):721-31. PubMed ID: 26104927
[TBL] [Abstract][Full Text] [Related]
3. Relationships between authorship contributions and authors' industry financial ties among oncology clinical trials.
Rose SL; Krzyzanowska MK; Joffe S
J Clin Oncol; 2010 Mar; 28(8):1316-21. PubMed ID: 20065190
[TBL] [Abstract][Full Text] [Related]
4. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments.
Roseman M; Milette K; Bero LA; Coyne JC; Lexchin J; Turner EH; Thombs BD
JAMA; 2011 Mar; 305(10):1008-17. PubMed ID: 21386079
[TBL] [Abstract][Full Text] [Related]
5. Industry sponsorship and authorship of clinical trials over 20 years.
Buchkowsky SS; Jewesson PJ
Ann Pharmacother; 2004 Apr; 38(4):579-85. PubMed ID: 14982982
[TBL] [Abstract][Full Text] [Related]
6. Association of industry sponsorship to published outcomes in gastrointestinal clinical research.
Brown A; Kraft D; Schmitz SM; Sharpless V; Martin C; Shah R; Shaheen NJ
Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1445-51. PubMed ID: 17101295
[TBL] [Abstract][Full Text] [Related]
7. The effects of industry funding and positive outcomes in the interpretation of clinical trial results: a randomized trial among Dutch psychiatrists.
Tijdink JK; Smulders YM; Bouter LM; Vinkers CH
BMC Med Ethics; 2019 Sep; 20(1):64. PubMed ID: 31533704
[TBL] [Abstract][Full Text] [Related]
8. Industry Collaboration and Primary Guest Authorship of High-Impact Randomized Clinical Trials: A Cross-Sectional Study.
Roper N; Korenstein D
J Gen Intern Med; 2015 Oct; 30(10):1421-5. PubMed ID: 25832619
[TBL] [Abstract][Full Text] [Related]
9. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials.
Bhandari M; Busse JW; Jackowski D; Montori VM; Schünemann H; Sprague S; Mears D; Schemitsch EH; Heels-Ansdell D; Devereaux PJ
CMAJ; 2004 Feb; 170(4):477-80. PubMed ID: 14970094
[TBL] [Abstract][Full Text] [Related]
10. Outcomes, Interventions and Funding in Randomised Research Published in High-Impact Journals.
Grey P; Grey A; Bolland MJ
Trials; 2018 Oct; 19(1):592. PubMed ID: 30373636
[TBL] [Abstract][Full Text] [Related]
11. Differences in Funding Sources of Phase III Oncology Clinical Trials by Treatment Modality and Cancer Type.
Jairam V; Yu JB; Aneja S; Wilson LD; Lloyd S
Am J Clin Oncol; 2017 Jun; 40(3):312-317. PubMed ID: 25374144
[TBL] [Abstract][Full Text] [Related]
12. The relationship of study and authorship characteristics on trial sponsorship and self-reported conflicts of interest among neuro-oncology clinical trials.
Raman S; Moraes FY; Mendez LC; Taunk NK; Suh JH; Souhami L; Slotman B; Kongkham P; Spratt DE; Berlin A; Marta GN
J Neurooncol; 2018 Aug; 139(1):195-203. PubMed ID: 29869023
[TBL] [Abstract][Full Text] [Related]
13. The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology.
Barton S; Peckitt C; Sclafani F; Cunningham D; Chau I
Eur J Cancer; 2015 Dec; 51(18):2732-9. PubMed ID: 26608121
[TBL] [Abstract][Full Text] [Related]
14. Funding Support and Principal Investigator Leadership of Oncology Clinical Trials Using Radiation Therapy.
Giacalone NJ; Milani N; Rawal B; Catalano PJ; Nguyen PL; Schoenfeld JD; Tishler RB; Margalit DN
Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):34-43. PubMed ID: 29970311
[TBL] [Abstract][Full Text] [Related]
15. Author financial conflicts of interest, industry funding, and clinical practice guidelines for anticancer drugs.
Tibau A; Bedard PL; Srikanthan A; Ethier JL; Vera-Badillo FE; Templeton AJ; Ocaña A; Seruga B; Barnadas A; Amir E
J Clin Oncol; 2015 Jan; 33(1):100-6. PubMed ID: 25385736
[TBL] [Abstract][Full Text] [Related]
16. Associations between industry involvement and study characteristics at the time of trial registration in biomedical research.
Seidler AL; Hunter KE; Chartres N; Askie LM
PLoS One; 2019; 14(9):e0222117. PubMed ID: 31553736
[TBL] [Abstract][Full Text] [Related]
17. Do financial factors such as author page charges and industry funding impact on the nature of published research in infectious diseases?
Liyanage SS; Raina Macintyre C
Health Info Libr J; 2006 Sep; 23(3):214-22. PubMed ID: 16911128
[TBL] [Abstract][Full Text] [Related]
18. How do health consumer organisations in Australia manage pharmaceutical industry sponsorship? A cross-sectional study.
Lau E; Fabbri A; Mintzes B
Aust Health Rev; 2019 Aug; 43(4):474-480. PubMed ID: 30021681
[TBL] [Abstract][Full Text] [Related]
19. Review and Analysis of Publication Trends over Three Decades in Three High Impact Medicine Journals.
Ivanov A; Kaczkowska BA; Khan SA; Ho J; Tavakol M; Prasad A; Bhumireddy G; Beall AF; Klem I; Mehta P; Briggs WM; Sacchi TJ; Heitner JF
PLoS One; 2017; 12(1):e0170056. PubMed ID: 28107475
[TBL] [Abstract][Full Text] [Related]
20. Financial relationships in economic analyses of targeted therapies in oncology.
Valachis A; Polyzos NP; Nearchou A; Lind P; Mauri D
J Clin Oncol; 2012 Apr; 30(12):1316-20. PubMed ID: 22430267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
